The KINETIC 2 TRIAL is evaluating the safety and efficacy of three different doses of an investigational drug compared to a placebo on reducing tremors in adults diagnosed with essential tremor. The safety and efficacy of investigational drugs have not been established. There is no guarantee that this drug will be approved by a health authority, such as the US Food and Drug Administration (FDA).
Participation in the KINETIC 2 TRIAL lasts approximately 19 weeks, including 11 clinic visits and five phone calls from the study team.
Eligible individuals must:
- Be 18 to 80 years old
- Have had a formal diagnosis of essential tremor for at least three years with upper limb action tremors that impact both sides of the body
- Be willing to discontinue medications taken for the treatment of essential tremor at least 14 days prior to the study and for the study’s duration
- Be willing to use an acceptable method of contraception
- Be willing and able to comply with the study instructions
There are additional eligibility requirements and substance use restrictions, which can be explained if you’d like to learn more. All eligible participants will be randomly assigned (like the flip of a coin) to receive either the investigational drug or a placebo. A placebo is an inactive pill that looks like the investigational drug but contains no active medication.
If you are interested in seeing if you may qualify to take part in the KINETIC 2 TRIAL, please visit the study website at KINETIC2ETtrial.com to learn more and complete a pre-screener. Eligible participants may receive reasonable compensation for their time and travel.